Advertisement

 

 

Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.

Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
Author Information (click to view)

Qunaj L, Castillo JJ, Olszewski AJ,


Qunaj L, Castillo JJ, Olszewski AJ, (click to view)

Qunaj L, Castillo JJ, Olszewski AJ,

Advertisement

Leukemia & lymphoma 2017 10 11() 1-9 doi 10.1080/10428194.2017.1387912

Abstract

Using records from the National Cancer Data Base, we studied overall survival of CD20-negative variants of diffuse large B-cell lymphoma (DLBCL): primary effusion (PEL, N = 228), plasmablastic (PBL, N = 481), ALK-positive large B-cell (ALK + LBLC, N = 15), and human herpesvirus-8-positive DLBCL (HHV8 + DLBCL, N = 77). Three-year survival was 27% for PEL, 40% for PBL, 34% for ALK + LBCL, and 63% for HHV8 + DLBCL. Compared with unspecified DLBCL, and adjusting for clinical characteristics (including the HIV status), survival was significantly worse for PEL (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.31-1.90), PBL (HR 1.66; 95% CI, 1.41-1.95), and ALK + LBCL (HR, 2.70; 95% CI, 1.27-5.75), but not for HHV8 + DLBCL (HR, 0.89; 95% CI, 0.54-1.45). The HIV status was not an independent prognostic factor in PEL, PBL, or HHV8 + DLBCL. Advanced stage was prognostic for PBL (p = .0002), but not for ALK + LBCL (p = .96), or HHV8 + DLBCL (p = .28). In PEL and PBL survival significantly differed according to primary site. Novel therapeutic approaches are urgently needed for these rare diseases.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × four =

[ HIDE/SHOW ]